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Abstract
The objective of this paper was to determine whether the presence of more vs. fewer anxious symptom
features, at baseline, are associated with other clinical features and treatment outcomes in out-patients
with major depressive disorder (MDD). This single-blind, randomized trial enrolled 665 MDD out-
patients to compare the efficacy of two antidepressant medication combinations against escitalopram after
12-wk acute treatment and follow-up (total 28 wk). The sample was divided into those with greater (vs.
fewer) anxiety features using the anxiety/somatization subscale of the baseline 17-item Hamilton Rating
Scale for Depression. Baseline sociodemographic and clinical features, treatment features and outcomes
compared these two groups. Overall, 74.7% of participants met the threshold for ‘anxious features’. They
were more likely to be female, have other concurrent anxiety disorders, more severe depression, more
lethargic and melancholic features and poorer cognitive and physical functioning, quality of life and work
and social adjustment. In acute treatment, participants with anxious features received comparatively
higher doses of mirtazapine and venlafaxine and reported more side-effects. The groups with and without
anxious features did not differ in treatment outcomes and side-effect burden. Despite being associated
with a distinct clinical profile, baseline anxious features were not clinically useful in predicting acute
treatment outcomes or differential treatment response.
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Introduction
Anxiety, nervousness and other somatic symptoms
are common among patients with major depressive
disorder (MDD) (Fawcett & Kravitz, 1983), as are
anxiety disorders (Zimmerman et al. 2002). Anxious
features have much in common with MDD features.
For example, the 17-item Hamilton Rating Scale
for Depression (HAMD17 ; Cleary & Guy, 1977) con-
tains six anxiety/somatization items: psychic anxiety ;
somatic anxiety ; gastrointestinal somatic symptoms;
general somatic symptoms; hypochondriasis ; insight.
When high levels of anxiety symptoms occur
in the context of MDD, they have been associated
with greater severity of depressive illness, greater
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functional impairment (Joffe et al. 1993), greater
chronicity (van Valkenburg et al. 1984) and an in-
creased risk of suicidality (Tollefson et al. 1994).
Patients with anxious features have also been found to
have greater unemployment rates and less education
(Fava et al. 2004, 2006).
Patients with MDD and a high level of anxious
features may be less likely to respond to anti-
depressant treatment than patients with fewer anxious
features in most (Davidson et al. 2002; Fava et al. 1997,
2008 ; Flint & Rifat, 1997) but not all (Russell et al. 2001;
Tollefson et al. 1994) studies, regardless of medication
type. Furthermore, greater anxious features may be
associated with a delayed response to treatment or
greater side-effect burden (Fava et al. 2008).
Aims of the study
This report evaluates whether anxious symptom
features are associated with any baseline socio-
demographic or clinical features in out-patients with
non-psychotic, recurrent or chronic MDD andwhether
anxious features divided into those with more vs.
fewer anxious features are associated with treatment
outcomes or side-effect burden for the full sample,
or with outcomes or side-effect burden among three
antidepressant medication options (a single medi-
cation and two different medication combinations).
Method
Study overview
This study was conducted using a large sample ob-
tained from the Combining Medications to Enhance
Depression Outcomes (CO-MED) trial (Rush et al.
2011). CO-MED was a 7-month, single-blind, rando-
mized trial that compared the efficacy of each of two
different antidepressant medication combinations vs.
escitalopram (Escit)+placebo (Pbo) (1 :1 :1 ratio) as a
first-step MDD treatment, including acute (12 wk) and
long-term continuation treatment (total 28 wk). Out-
patient participants with non-psychotic MDD were
recruited from six primary care and nine psychiatric
care sites across the United States. Study details and
methodology are available elsewhere (Rush et al. 2011).
Broad inclusion and minimal exclusion criteria en-
sured a reasonably representative participant sample.
Out-patient enrollees aged 18–75 yr met DSM-IV
TR (APA, 2000) criteria for either recurrent [o1
prior major depressive episode (MDE)] or chronic
(current MDE for o2 yr) MDD based on a clinical
interview, which was confirmed by a DSM-IV MDD
symptom checklist completed by the Clinical Research
Coordinator. Eligible participants had to be in the
index episode for o2 months and they had to have a
score o16 on the HAMD17 (Hamilton, 1960). Those
with a history of any psychotic illness, bipolar disorder
or in need of acute hospitalization were excluded. For
a full listing of exclusion criteria, see www.co-med.org.
The study protocol and all consent and study
procedures were approved by the Institutional Review
Boards at the National Coordinating Center (The
University of Texas Southwestern Medical Center at
Dallas), the University of Pittsburgh Data Coordinat-
ing Center, each participating regional centre and all
relevant clinical sites.
Baseline data
Sociodemographic and clinical features were gathered
at baseline. A score ofo7 on the anxiety/somatization
subscale of the baseline HAMD17 established the
presence of anxious features (Fava et al. 2008). The self-
report Psychiatric Diagnostic Screening Questionnaire
(PDSQ) (Zimmerman & Mattia, 2001a, b) established
the presence of current Axis I disorders (Rush et al.
2005). The Self-administered Comorbidity Question-
naire (Sangha et al. 2003) established the presence,
severity and functional impact of a wide range
of common general medical comorbidities (GMCs).
The presence of lethargic, melancholic and atypical
features was ascertained on the basis of specific
item scores on the 30-item Inventory of Depressive
Symptomatology – Clinician-rated (IDS-C30 ; Rush et al.
2003). Similarly, the presence of sleep disturbances
was ascertained on the basis of specific item scores on
the IDS-C30.
Antidepressant treatment
A 12-wk study period was chosen for the primary
analysis. Treatment visits were planned at baseline
andweeks 1, 2, 4, 6, 8, 10, 12 and at weeks 16, 20, 24 and
28. Dosage adjustments were guided by the CO-MED
Operations Manual (available at www.co-med.org),
which utilized measurement-based care to provide
personally tailored and vigorous dosing (Trivedi &
Daly, 2007 ; Trivedi et al. 2007), with dosage adjust-
ments based on the 16-item Quick Inventory of De-
pressive Symptomatology – Clinician-rated (QIDS-C16)
(Rush et al. 2003, 2006), which was extracted from the
IDS-C30, the Frequency, Intensity and Burden of Side
Effects Rating (FIBSER; Wisniewski et al. 2006) and
the measurement of participant adherence obtained at
each treatment visit.
Treatment was randomly assigned, stratified by
clinical site using a Web-based randomization system
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(Wisniewski et al. 2004). Random block sizes of three
and six were used to minimize the probability of
identifying the next treatment assignment. Dosing
schedules were based on prior reports (Fava, 2001 ;
Leuchter et al. 2008; McGrath et al. 2006). Doses were
increased only in the context of acceptable side-effects.
Details of the dosing schedule are available elsewhere
(Rush et al. 2011). Participants could exit the study
if unacceptable or intolerable side-effects occurred
that could not be resolved with dose reduction or
medication treatment.
Medication blinding
One medication in each treatment group was open
(participant and study personnel unblinded), while
the second medication was blinded (participant
only). Thus, all participants took two types of ‘pills ’.
Specifically, in the Escit+Pbo group, the Pbo medi-
cation was blinded; in the bupropion-sustained
release (Bup-SR)+Escit group, Escit was blinded;
and in the venlafaxine-extended release (Ven-XR)+
mirtazapine (Mirt) group, Mirt was blinded.
Concurrent treatments
Only protocol antidepressant medications were al-
lowed. Treatments with possible antidepressant
effects were proscribed, as were anxiolytics, sedative
hypnotics and depression-targeted, empirically vali-
dated psychotherapies for depression. Other therapies
(e.g. supportive, couples, occupational therapy) were
allowed, as were medications for any GMC. Given the
Bup-SR inhibition of the 2D6 isoenzyme, we alerted
clinicians to recognize non-protocol medications (e.g.
type 1C antiarrhthmics, b blockers, etc.) for which
serum levels or dose adjustments might be needed.
Medications to treat antidepressant medication side-
effects were allowed (clinician judgement) in order to
mimic clinical practice and enhance retention.
Research outcomes
Outcome assessments were collected at baseline and at
all subsequent treatment visits. The primary outcome,
symptom remission, was based on the 16-item Quick
Inventory of Depressive Symptomatology – Self-
Report (QIDS-SR16 ; Rush et al. 2003, 2006 ; Trivedi et al.
2007). Remission was ascribed a priori based on the last
two consecutive measurements obtained during the
12-wk acute trial to ensure that a single ‘good week’
was not falsely signalling remission. At least one of
these ratings had to be <6, while the other had to be
<8. If participants exited before 12 wk, their last two
consecutive QIDS-SR16 scores were used to ascribe
remission. Those who exited before having two post-
baseline measures were considered not remitted.
Participants could exit the study if they had re-
ceived a maximally tolerated dose(s) for o4 wk by
week 8 without receiving a o30% reduction in base-
line QIDS-C16. They could enter continuation treat-
ment (weeks 12–28) if they had received an acceptable
benefit (defined as a QIDS-C16 f9 by week 12) or if
they reached a QIDS-C16 of 10–13 with clinician and
participant judging the benefit to be substantial
enough to indicate a treatment continuation. Thus, vir-
tually all participants entering the continuation phase
had at least a 40% reduction in baseline QIDS-C16.
Additional baseline measures included the IDS-C30
(Rush et al. 1996, 2000, 2003), of which 28 items are
rated 0–3 (range 0–84, with higher numbers indicating
more severe depression), the Work and Social Adjust-
ment Scale (Mundt et al. 2002), (five items; range 0–40;
higher numbers indicate greater impairment) and the
Quality of Life Inventory (Frisch, 1994 ; Frisch et al.
1992, 2005) (overall life satisfaction is calculated as the
mean of 17 weighted items resulting in a possible
score ranging from x6 to +6). Cognition, fatigue,
sleepiness and anhedonia were measured using the
Cognitive and Physical Functioning Questionnaire
(Fava et al. 2009), a unifactorial scale consisting of
seven questions with ratings from 1–6, and side-effect
burden was measured using the FIBSER.
Statistical analyses
Descriptive statistics, including measures of central
tendency and dispersion, were computed for con-
tinuous data. Frequency distributions were estimated
for categorical data. The appropriate parametric (e.g.
t test) or nonparametric test (e.g. x2, Wilcoxon tests)
were used to ensure a balanced distribution of the
sociodemographic, psychiatric and medical charac-
teristics among those with and without anxious de-
pression.
At 12 and 28 wk, unadjusted and adjusted treat-
ment features and outcomes were compared among
those with and without anxious depression using re-
gression models. The type of regression models varied
by outcome and included linear regression, logistic
regression, ordinal logistic regression and negative
binomial regression models. Potential confounders
were identified using a stepwise logistic regression
model with an indicator of anxious depression as
the outcome and all other baseline characteristics as
independent variables. Those variables that remained
in the final stepwise model were considered as
potential confounders in the adjusted models. The
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moderating effect of anxious depression on treatment
was evaluated on two outcomes, severity of depression
(QIDS-SR16) and side-effect burden (FIBSER burden),
both at 12 and 28 wk. For severity of depression a
linear regression model was fit, and for side-effect
burden an ordinal logistic regression model was fit.
Both models included main effects for treatment and
anxious depression. The moderating effect of anxiety
and treatment on time to remission (QIDS-SR16 f5)
was examined using Kaplan–Meir curves and a log-
rank test to determine if the curves were significantly
different. All analyses are considered to be exploratory
in nature and a type I error or a p value<0.05 was used
as a threshold to identify statistical significance. No
adjustments were made for multiple comparisons, so
results should be interpreted accordingly.
Results
A total of 835 out-patients were offered consent to be
screened for the study (Fig. 1). Of these, 734 (87.9%)
signed consent. Of those screened, 665 (90.6%) were
eligible and were enrolled and randomly assigned to
one of the three treatment groups. Of these, 497/665
(74.7%) met the criterion for anxious features.
A larger percentage of those with more anxious
features were women compared with those with fewer
anxious features (71.4% vs. 57.7%; p=0.0010) (Table 1).
Slightly more participants with more anxious features
reported sexual abuse before age 18 than those with
fewer anxious features (23.6% vs. 16.8%, p=0.0651)
(Table 2).
At baseline, participants with more anxious
features had higher rates of concurrent agoraphobia
(p<0.0001), panic disorder (p=0.0002), generalized
anxiety disorder (p<0.0001), post-traumatic stress
disorder (p=0.0043) and social phobia (p=0.0006),
and more psychiatric disorders overall (p<0.0001)
than the less anxious group. The two groups did not
differ in the number of concurrent GMCs at baseline
(Table 3).
Participants with more anxious features had greater
baseline depressive severity than the less anxious
based on the HAMD17, QIDS-SR16, QIDS-C16, and the
IDS-C30 (all p<0.0001) and the more anxious were
more likely to have melancholic (p<0.0001) or leth-
argic (p<0.0001) depressive symptom features at
baseline. Worse cognitive function (p=0.0001), lower
quality of life (p=0.0008) and poorer work and worse
social adjustment (p=0.0017) at baseline characterized
the more anxious group (Table 4).
Early termination rates did not distinguish the two
groups defined by baseline anxious features. Severity
of depression did not differentiate between the two
groups at weeks 12 or 28, nor did quality-of-life scores.
At week 12, participants with more anxious features
had greater side-effect burden than those with less
anxious features (p=0.0049). The more anxious par-
ticipants were prescribed higher doses of venlafaxine
(p=0.0485) and Mirt (p=0.0444) than the less anxious
participants. At week 28 participants with greater
baseline anxiety still had a greater side-effect burden
than the less anxious (p=0.0009), but doses of anti-
depressant medications were not different (Table 5).
The two groups (more or less anxious) did not differ
in time to response to any of the three treatments at
either 12 wk or 28 wk (Fig. 2). In addition, more vs.
fewer anxious features was unrelated to treatment
outcomes or side-effect burden among the three treat-
ment options (Table 6).
To further evaluate the relevance of baseline anxiety
on outcomes, we divided the whole group into those
with vs. those without any formal anxiety disorder
based on the PDSQ. Of those with a formal anxiety
disorder 46.5% (120/258) responded and 27.9%























Fig. 1. CONSORT flow diagram.
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anxious’, but who had one or more formal anxiety
disorders by PDSQ, 50% (25/50) responded (p=0.651)
and 32.0% (16/50) remitted (p=0.5527).
Turning to those without a formal anxiety disorder,
of those considered to be ‘more anxious’, 57.9%
(129/223) responded, and 48.1% (113/235) remitted.
On the other hand, those without a formal anxiety
disorder and fewer anxious features, 53.7% (60/112)
responded (p=0.466) and 45.8% (45/118) remitted
(p=0.6801).









x2 t test p value
Gender 10.81 0.001
Male 142 (28.6) 71 (42.3)
Female 355 (71.4) 97 (57.7)
Race 1.66 0.436
White 316 (65.8) 115 (70.6)
Black 133 (27.7) 41 (25.2)
Other 31 (6.5) 7 (4.3)
Age (yr) 0.32 0.852
18–29 104 (20.9) 32 (19.0)
30–54 287 (57.7) 98 (58.3)
55–75 106 (21.3) 38 (22.6)
Employed 238 (47.9) 93 (55.4) 2.80 0.094
Mean (S.D.) Mean (S.D.)
Age (yr) 42.6 (13.0) 43.0 (13.0) 0.33 0.745
Education (yr) 13.7 (2.9) 13.9 (3.1) 0.46 0.645
Monthly household income ($) 2718 (5956) 2562 (2990) 1.29 0.256










Age at first episode <18 yr 220 (44.3) 76 (45.8) 0.12 0.7335
Lifetime severity of suicidality 5.44 0.4886
None 139 (28.8) 59 (36.9)
Thoughts of dying 137 (28.4) 40 (25.0)
Suicidal thoughts 76 (15.7) 22 (13.8)
Specific method 42 (8.7) 17 (10.6)
Plan/gesture 31 (6.4) 7 (4.4)
Preparation 11 (2.3) 3 (1.9)
Attempt 47 (9.7) 12 (7.5)
Neglected before age 18 yr 181 (36.4) 59 (35.3) 0.06 0.7999
Emotionally abused before age 18 yr 203 (40.8) 58 (34.7) 1.96 0.1616
Physically abused before age 18 yr 99 (19.9) 32 (19.2) 0.05 0.8314
Sexually abused before age 18 yr 117 (23.6) 28 (16.8) 3.40 0.0651
Current episode duration o2 yr 279 (56.1) 89 (53.6) 0.32 0.5713
Chronic/recurrent depression 0.35 0.8397
Chronic only 110 (22.1) 36 (21.7)
Recurrent only 218 (43.9) 77 (46.4)
Both 169 (34.0) 53 (31.9)
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Discussion
About three out of four participants in this study met
the threshold for more anxious symptoms, which is
higher than the 44–46% found in the depressed out-
patient sample of our earlier Sequenced Treatment
Alternatives to Relieve Depression study (STAR*D;
Fava et al. 2004, 2006) and the 51.2% found in a recent
depressed inpatient sample (Wiethoff et al. 2010).
CO-MED required that participants have either re-
current or chronic depression and that the index epi-
sode had to exceed 2 months in duration. Anxious
features are more common among participants with a
chronic index episode of depression (Gilmer et al. 2008).
Perhaps the inclusion criteria in the current study ac-
count for the high rate of more anxious participants.
Those with more anxious features were more likely
to be female (>70%) than the less anxious (57%), re-
ported elsewhere (Fava et al. 2004, 2006). There were
no significant differences between the two groups in
employment status, educational level or household
income, although some studies have found that those
with more anxious features have lower educational
attainment, greater unemployment and poorer social
circumstances (Fava et al. 2004, 2006 ; Wiethoff et al.
2010). In addition, we did not find an earlier onset
of illness, greater suicidality or greater duration of ill-
ness in the more anxious compared with the less an-
xious group. Childhood sexual, physical or emotional
abuses are known risk factors for the development of
anxiety and depressive disorders in adults (Gibb et al.
2007; Young et al. 1997). In this study, such childhood
adversities did not differentiate those with more vs.
less anxious features.
Participants with more anxious features had more
concurrent formal anxietydisorders basedon thePDSQ
and more psychiatric disorders overall – including
agoraphobia, generalized anxiety disorder, panic
disorder, post-traumatic stress disorder and social
phobia – which is consistent with prior reports (Fava
et al. 2004, 2006). Thus, anxiety symptom features (as
a dimension) are highly related to the likelihood of
syndromal diagnoses of various anxiety disorders.
Comorbid depression is a well-known feature of
chronic medical illnesses such as asthma (Eisner et al.
2005), coronary artery disease (Spertus et al. 2000) and
congestive heart failure (Rumsfield et al. 2003). In this
study, however, anxious features were not associated










Agoraphobia 65 (13.1) 4 (2.4) 15.45 <0.0001
Alcohol abuse 45 (9.1) 22 (13.1) 2.24 0.1346
Drug abuse 27 (5.4) 8 (4.8) 0.11 0.7364
Generalized anxiety 119 (23.9) 12 (7.1) 22.40 <0.0001
Hypochondriasis 26 (5.2) 3 (1.8) 3.57 0.0587
Obsessive-compulsive 66 (13.3) 13 (7.7) 3.68 0.0550
Panic 61 (12.3) 4 (2.4) 13.93 0.0002
Post-traumatic stress 71 (14.3) 10 (6.0) 8.15 0.0043
Social phobia 150 (30.2) 28 (16.7) 11.70 0.0006
Somatoform 19 (3.8) 2 (1.2) 2.85 0.0916
No. of psychiatric disorders 23.91 <0.0001
0 199 (40.1) 97 (57.7)
1 119 (24.0) 40 (23.8)
2 74 (14.9) 18 (10.7)
3 42 (8.5) 8 (4.8)
o4 62 (12.5) 5 (3.0)
No. of treated SCQ health problems 3.303 0.3473
0 224 (49.2) 84 (50.3)
1 113 (22.8) 45 (26.9)
2 74 (14.9) 24 (14.4)
o3 65 (13.1) 14 (8.4)
SCQ, Self-Administered Comorbidity Questionnaire.
Values that meet the criterion for statistical significance are in bold.
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with greater rates of concurrent, comorbid general
medical illnesses, although up to half of the depressed
participants had at least one comorbid health problem.
The participants with more anxious features were
more severely depressed and they displayed more
lethargic and melancholic features than the less
anxious – although not more atypical features – which
fits previous findings (Rush et al. 2006; Trivedi et al.
2006). Given the greater severity and psychiatric co-
morbidity in the more anxious, it is not surprising that
greater impairment in cognitive and physical func-
tioning, lower quality of life and greater difficulty in
work and social adjustment was also present.
Contrary to expectation, the two groups (more vs.
less anxious) did not differ in terms of depressive
symptom outcomes at either 12 or 28 wk, nor did they
differ in drop-out rates (early terminations). Our find-
ing that those with more anxious features did not
have a worse depression outcome than those with
fewer anxious features at baseline is contrary to some
(Davidson et al. 2002; Fava et al. 1997, 2008 ; Flint &
Rifat, 1997) but not all (Russell et al. 2001; Tollefson
et al. 1994) prior reports. It could be due to : (1) the
risk that all of these reports (this one included) are
secondary analyses, which risk false positive findings;
(2) the sample herein is one in which over half of the
participants were in the index episode for at least
two (and in many cases several more) years ; and/or
(3) the requirement of at least 6 months than the
current episode or other factors. It should be noted,
however, thatwe did not have a Pbo comparison. Thus,
there could be a drug–Pbo response difference within
either or both the more and less anxious groups.
At the end of acute treatment (week 12), partici-
pants with more anxious features reported higher
side-effect burden than the less anxious participants.
This finding could be due to the higher doses of MIRT
and venlafaxine prescribed in acute treatment for the
more anxious (vs. less) participants. Previous reports
with other treatments (Fava et al. 2008) have also
found that participants with more anxious features
have a greater frequency, intensity and burden of side-
effects during treatment compared with less anxious
depressed participants. Thus, baseline anxiety features
may put patients at greater risk for side-effect burden,
due to the use of larger doses of medication or to a
heightened focus on bodily symptoms or greater
sympathetic nervous system arousal.
However, at week 28, participants with more an-
xious features reported higher side-effect burden even









x2 t test p value
QIDS-SR16 20.23 0.0002
0–10 None/mild 53 (11.0) 28 (17.2)
11–15 Moderate 161 (33.3) 77 (47.2)
16–20 Severe 212 (43.9) 48 (29.4)
21–27 Very severe 57 (11.8) 10 (6.1)
IDS-C30
Lethargic depression 360 (72.4) 92 (54.8) 18.01 <0.0001
Atypical features 79 (15.9) 24 (14.3) 0.25 0.6181
Melancholic features 114 (25.3) 10 (6.5) 24.86 <0.0001
Mean (S.D.) Mean (S.D.)
QIDS-SR16 16.0 (4.2) 14.0 (4.1) 5.11 <0.0001
IDS-C30 39.6 (9.0) 33.2 (7.6) 8.97 <0.0001
HAMD17 25.2 (4.5) 19.8 (3.0) 17.30 <0.0001
QIDS-C16 16.3 (3.4) 45.5 (3.1) 6.06 <0.0001
CPFQ 28.1 (5.8) 26.1 (5.7) 3.89 0.0001
QOLI x1.3 (1.9) x0.8 (1.8) 3.35 0.0008
WSAS 25.5 (8.7) 25.1 (9.0) 9.8218 0.0017
QIDS-SR16, 16-item Quick Inventory of Depressive Symptomatology Self-Rated; IDS-C30, 16-item Inventory of Depressive
Symptomatology – Clinician-Rated ; HAMD17, 17-item Hamilton Rating Scale for Depression; QIDS-C16 16-item Quick Inventory
of Depressive Symptomatology – Clinician-Rated ; CPFQ, Cognitive and Physical Functioning Questionnaire ; QOLI, Quality of
Life Inventory ; WSAS, Work and Social Adjustment Scale.
Values that meet the criterion for statistical significance are in bold.
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x2 b p value OR p value OR p value
Week 12
Weeks in treatment
<4 69 (13.9) 24 (14.4) 0.02 0.8823
<8 107 (21.6) 37 (22.2) 0.03 0.8744
Last FIBSER burden 1.840 0.0034 1.862 0.0049
No impairment 245 (51.8) 99 (63.5)
Minimal/mild 170 (35.9) 45 (28.8)
Moderate/marked 42 (8.9) 11 (7.1)
Severe/intolerable 16 (3.4) 1 (0.6)
Last QIDS-SR16 <6 176 (35.6) 66 (39.5) 0.806 0.2787 0.986 0.9458
% QIDS-SR16 reduction o50 249 (51.8) 85 (52.5) 1.060 0.7653 1.075 0.7274
Mean (S.D.) Mean (S.D.)
Weeks in treatment 9.9 (3.9) 9.8 (4.0) 0.03 0.8512
Open med dose (mg)
Last bupropion 285 (121) 299 (119) 0.72 0.3961
Last escitalopram 16.8 (5.5) 16.9 (5.0) 0.034 0.8537
Last venlafaxine 198 (81) 174 (83) 3.89 0.0485
Blinded med dose (mg)
Last escitalopram 12.4 (8.4) 12.7 (7.8) 0.001 0.9730
Last placebo (no. of pills) 1.3 (0.8) 1.4 (0.7) 0.47 0.4940
Last mirtazapine 21.2 (15.6) 16.4 (15.5) 4.04 0.0444
Last QIDS-SR16 8.5 (5.6) 7.2 (4.6) 0.574 0.2906
% QIDS-SR16 reduction x45 (35.3) x47 (30.8) 2.077 0.5513
Last QOLI 0.09 (2.37) 0.41 (2.15) x0.053 0.8246
Week 28
n (%) n (%)
Last FIBSER burden 2.31 0.0002 2.21 0.0009
No impairment 266 (56.0) 108 (69.2)
Minimal/mild 147 (30.9) 37 (23.7)
Moderate/marked 48 (10.1) 11 (7.1)
Severe/intolerable 14 (2.9)
Last 2 QIDS-SR16 <6/8 217 (44.1) 75 (45.2) 0.95 0.7805 1.18 0.4426
% QIDS-SR16 reduction o50 280 (58.5) 94 (58.4) 0.98 0.9113 1.05 0.8082
Mean (S.D.) Mean (S.D.)
Weeks in treatment 20.0 (10.5) 19.8 (10.6) 0.17 0.6762
Open med dose (mg)
Last bupropion 273 (135) 266 (143) 0.022 0.8821
Last escitalopram 15.6 (7.2) 15.8 (6.3) 0.045 0.8316
Last venlafaxine 184 (96) 160 (86) 3.45 0.0634
Blinded med dose (mg)
Last escitalopram 11.4 (8.7) 11.8 (8.3) 0.048 0.8278
Last placebo (no. of pills) 0.61 (0.85) 0.85 (0.89) 4.31 0.0379
Last mirtazapine 18.5 (16.1) 16.4 (17.5) 1.06 0.3043
Last QIDS-SR16 7.8 (5.8) 6.8 (4.8) 1.03 0.6755
% QIDS-SR16 reduction x50 (36.3) x50 (31.3) 0.65 0.8579
Last QOLI 0.42 (2.44) 0.61 (2.22) x0.05 0.8518
OR, Odds ratio ; FIBSER, Frequency, Intensity, and Burden of Side Effects Rating ; QIDS-SR16, 16-item Quick Inventory of
Depressive Symptomatology – Self-Rated ; QOLI, Quality of Life Inventory.
Values that meet the criterion for statistical significance are in bold.
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when there was no difference in medication dosage.
A large-scale study of>50 000 participants (Haug et al.
2004) has shown that when both anxiety and de-
pression are present, there is a higher prevalence of
somatic symptoms than when anxiety or depression
alone are present. It has been suggested that the
threshold for experiencing somatic symptoms may
be lower in participants with concurrent anxiety and
depression (Katon et al. 1991). Thus, the use of the self-
report FIBSER to measure side-effect burden may
have detected participants with residual anxious
depression who are somatizing rather than actually
experiencing side-effects.
When we compared the three treatment options in
this study, membership in the more or less anxious
group was unrelated to treatment outcomes or side-
effect burden. Thus, anxious features did not moderate
outcomes among the three treatment options in this
study, which is similar to findings in STAR*D (Rush
et al. 2008). However, STAR*D found that, overall,
those with more anxious features had poorer out-
comes than those with fewer anxious features.
This study had several limitations. We did not
utilize a clinician-administered structured diagnostic
interview, which could have provided a more accurate
diagnostic picture. Also, the results can only be
generalized to out-patients with chronic or recurrent
MDD, in which the index episode is at least 2 months
in duration. Most of the assessment tools relied on
participant self-assessment.
In summary, this single-blind, randomized trial
found anxious features to be highly prevalent in these
nonpsychotic depressed out-patients, over half of
whom were in a chronic episode. Anxious features
were more common in women than in men. Baseline
anxious features were associated with a distinct clini-
cal profile but, in this study, we found no association
between anxious features at baseline and overall out-
come or with differential treatment outcomes among
the three antidepressant medication options.
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Fig. 2. Time to response in the first 12 wk and over 28 wk of treatment.
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n (%) n (%) n (%) n (%) n (%) n (%) p value
Week 12
Early termination 57 (32.2) 40 (25.6) 40 (24.4) 13 (29.5) 15 (22.1) 17 (30.4) 0.5452
Last QIDS-SR16 <6 60 (34.3) 56 (35.9) 60 (36.8) 22 (50.0) 25 (36.8) 19 (34.5) 0.2400
% QIDS-SR16 reduction o50 89 (51.7) 78 (51.0) 82 (52.6) 22 (51.2) 35 (53.8) 28 (51.9) 0.9323
Last FIBSER burden 0.2588
No impairment 91 (53.8) 73 (50.0) 81 (51.3) 27 (67.5) 44 (67.7) 28 (54.9)
Minimal/mild 58 (34.3) 55 (37.7) 57 (36.1) 11 (27.5) 19 (29.2) 15 (29.4)
Moderate/marked 13 (7.7) 14 (9.6) 15 (9.5) 1 (2.5) 2 (3.1) 8 (15.7)
Severe/intolerable 7 (4.1) 4 (2.7) 5 (3.2) 1 (2.5) 0 (0.0) 0 (0.0)
Mean (S.D.) Mean (S.D.) Mean (S.D.) Mean (S.D.) Mean (S.D.) Mean (S.D.)
Last QIDS-SR16 8.4 (5.5) 8.4 (5.6) 8.6 (5.9) 6.8 (4.6) 6.8 (4.0) 8.0 (5.1) 0.5729
% QIDS-SR16 reduction x45 (34.2) x45 (34.9) x46 (37.2) x43 (36.6) x51 (27.9) x45 (29.1) 0.5488
Week 28
n (%) n (%) n (%) n (%) n (%) n (%)
Early termination 69 (39.0) 56 (35.9) 57 (34.8) 15 (34.1) 22 (32.4) 25 (44.6) 0.3120
Last 2 QIDS-SR16 <6/8 81 (46.3) 69 (44.5) 67 (41.4) 20 (46.5) 32 (47.1) 23 (41.8) 0.9723
% QIDS-SR16 reduction o50 103 (59.9) 89 (58.6) 88 (56.8) 22 (52.4) 40 (61.5) 32 (59.3) 0.5925
Last FIBSER burden 0.8682
No impairment 99 (58.2) 88 (59.9) 79 (50.0) 29 (72.5) 47 (72.3) 32 (62.7)
Minimal/mild 50 (29.4) 44 (29.9) 53 (33.5) 10 (25.0) 16 (24.6) 11 (21.6)
Moderate/marked 14 (8.2) 11 (7.5) 23 (14.6) 1 (2.5) 2 (3.1) 8 (15.7)
Severe/intolerable 7 (4.1) 4 (2.7) 3 (1.9) 0 (0.0) 0 (0.0) 0 (0.0)
Mean (S.D.) Mean (S.D.) Mean (S.D.) Mean (S.D.) Mean (S.D.) Mean (S.D.)
Last QIDS-SR16 7.4 (5.5) 7.9 (5.7) 8.3 (6.1) 6.7 (4.7) 6.1 (4.4) 7.6 (5.2) 0.5034
% QIDS-SR16 reduction x51 (37.0) x50 (33.6) x48 (38.1) x46 (33.7) x55 (30.9) x48 (29.7) 0.4611
Bup-SR, Bupropion-sustained release ; Escit, escitalopram; Pbo, placebo ; Ven-XR, venlafaxine-extended release ; Mirt,
mirtazapine ; QIDS-SR16, 16-item Quick Inventory of Depressive Symptomatology – Self-Rated ; FIBSER, Frequency, Intensity,
and Burden of Side Effects Rating.
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